Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MARKET INSIGHT: Insulin delivery techs and the role of long-term cost structures

This article was originally published in Clinica

Executive Summary

Uptake of insulin pump therapy varies sharply from market to market. In the US, over a third of Type I diabetics use a pump, but in Europe this can be as low as the mid-single digits. The speed of new technology roll-outs can be affected by the previous therapy policy of any particular country, but are stakeholders doing enough to ensure that more eligible individuals can access this proven delivery means? IBI principal analyst Ashley Yeo investigates

Topics

UsernamePublicRestriction

Register

MT099718

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel